

2021 Conflicts of Interest Report

Committee: PD-L1 Testing of Patients with Lung Cancer for Selection of Immunooncology Therapies—Expert Panel

Chair: Lynette Sholl, MD, FCAP, Chair

Staff: Christina B. Ventura, MPH, MLS(ASCP)

Date: March 2021

Interest/Activity Type	Entity	Description (if applicable)
Lynette Sholl, MD, FCAP		
research grants	Genentech	Research grants to my institution are related to my Co-Investigator status on a project at DFCI/BWH (PI: Raphael Bueno; Cancer immunotherapy research with imCORE Program). 2018-2020
consulting fees or advisory board	Genentech	Consulting fees are related to an upcoming role as chair of the ML41591 steering committee for a clinical trial of targeted therapies for genomic driver alterations in NSCLC in the neoadjuvant setting. 2020-Current/ongoing
consulting fees or advisory board	EMD Serono	Fees for educational lecture on lung cancer biomarker testing. 2019-2019
speakers' bureau/lecture fees/honoraria	AstraZeneca	Honoraria and international travel reimbursement for a lecture on lung cancer immunotherapy biomarkers. 2018-2018
Mark Awad, MD, PhD		
consulting fees or advisory board	Maverick	2019-2019
consulting fees or advisory board	Blueprint Medicine	2018-2018
consulting fees or advisory board	Syndax	2017-2017
research grants	Bristol-Myers Squibb	2017-current/ongoing
research grants	Lilly	Prior to 2017-current/ongoing
research grants	Genentech	Prior to 2017-current/ongoing
research grants	AstraZeneca	Prior to 2017-current/ongoing
consulting fees or advisory board	Nektar	2018-2018

Disclaimer The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on May 10, 2021. The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.



Research grants	Boehringer-Ingelheim	Grant to the Hospital for implementation of EGFR testing in non-small cell lung cancer. 2019-current/ongoing
consulting fees or advisory board	Amgen	Honorarium for lung cancer biomarker testing advisory board participation. 2020-2020
Larissa V. Furtado, MD		
other remunerations	Dako/Agilent	I participated as a pathologist in a PD-L1 triple negative breast cancer reproducibility study for PD-L1 22C3 IHC test. My work was part of a work agreement between ARUP PharmaDx department and Dako/Agilent. Dako payed ARUP for my work on this study, which was transferred by ARUP to my internal development account. 2019-2019
David Muren Hwang, MD, PhD		
research grants	Boehringer-Ingelheim	Grant to the Hospital for implementation of EGFR testing in non-small cell lung cancer. 2019-Current/ongoing
consulting fees or advisory board	Amgen	Honorarium for lung cancer biomarker testing advisory board participation. 2020-2020
Gregory Kalemkerian, MD		
research grants	Merck	Funds to University of Michigan. Prior to 2018-current/ongoing
research grants	Abbvie	Funds to University of Michigan. Prior to 2018-current/ongoing
research grants	Takeda	Funds to University of Michigan. Prior to 2018-current/ongoing
Lauren Ritterhouse, MD, PhD		
speakers' bureau/lecture fees/honoraria	Loxo Oncology	Loxo-292 advisory board honoraria. 2019-2019
Jennifer Sauter, MD		
stock options/bonds	MERCK & CO INC NEW COM	
stock options/bonds	PFIZER INC	
stock options/bonds	THERMO FISHCER SCIENTIFIC	
Paul E Swanson, MD		
position of influence	College of American Pathologists	As a member of the expert panel for updates to the IHC validation guidelines, my involvement in other CAP Quality Centers might be seen as a potential for undue influence. I have not requested reimbursement for meeting expenses and this have not experienced a financial benefit from this activity. Prior to 2018-current/ongoing
position of influence	Canadian Association of Pathologists	As a member of a CAP supports panel that developed PD-L1 testing guidelines for Canada, I might be seen as a person with undue influence on the development of related guidelines by the College. Because I did not ask for reimbursement of meeting-related expenses, I have not



position of influence	Wolters-Kluwer (publisher)	experienced a financial benefit from his activity. Prior to 2018-current/ongoing As Editor-in-Chief of Applied Immunohistochemistry and Molecular Morphology (Wolters-Kluwer, publisher), I might be seen as having undue influence on conversations relating to quality of evidence on topics related to guidelines development. 2020-Current/ongoing I have previously included my membership in committees relating to pathology education in the American Society for Clinical Pathology, but have not been active in that role since spring of 2017.
Ignacio I. Wistuba, MD		
consulting fees or advisory board	Genentech/Roche	2017-current/ongoing
research grants	Genentech/Roche	2017-current/ongoing
speakers' bureau/lecture fees/honoraria	Genentech/Roche	2017-current/ongoing
consulting fees or advisory board	Astra Zeneca/Medimmune	Prior to 2017-2018
research grants	Astra Zeneca/Medimmune	Prior to 2017-current/ongoing
consulting fees or advisory board	GlaxoSmithKline	
speakers' bureau/lecture fees/honoraria	Bristol-Myers Squibb	
consulting fees or advisory board	Bristol-Myers Squibb	2017-2019
consulting fees or advisory board	HTG Molecular	2018-current/ongoing
research grants	HTG Molecular	2017-current/ongoing
consulting fees or advisory board	Guardant Health	2019/2019
consulting fees or advisory board	Pfizer	2018/2018
speakers' bureau/lecture fees/honoraria	Pfizer	2017/2018
research grants	Pfizer	2018/Current/Ongoing

Disclaimer The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on May 10, 2021. The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.



consulting fees or advisory board	Merck	2017/2018
research grants	Merck	2018/Current/Ongoing
consulting fees or advisory board	Bayer	2018/2019
research grants	Bayer	2019/Current/Ongoing
consulting fees or advisory board	MSD	2017/2018
speakers' bureau/lecture fees/honoraria	MSD	2017/2018
research grants	Oncoplex	2017/2018
research grants	DepArray	2017/2019
research grants	Adaptive	2018/Current/Ongoing
research grants	Adaptimmune	2017/Current/Ongoing
research grants	EMD Serono	2018/Current/Ongoing
research grants	Takeda	2018/Current/Ongoing
research grants	Amgen	2019/Current/Ongoing
research grants	Karus	2019/Current/Ongoing
research grants	Johnson & Johnson	Prior to 2017/Current/Ongoing
research grants	4D	Prior to 2019/Current/Ongoing
research grants	Novartis	Prior to 2019/Current/Ongoing
Mari Mino-Kenudson, MD		
consulting fees or advisory board	H3Biomedicine	Pathology consultant. Prior to 2018-Current/Ongoing
consulting fees or advisory board	AstraZeneca	Pathology consultant. 2019-Current/Ongoing
research grant	Novartis	Assessing pathology specimens as a co-investigator in a project funded by the company (a research grant to institution). 2019-Current/Ongoing



Main Employment:

Entity	Description
Lynette Sholl, MD, FCAP	Brigham and Women's Hospital
Larissa V. Furtado, MD	University of Utah
Mark Awad, MD, PhD	Dana-Farber Cancer Institute
Mary Beth Beasley, MD	Icahn School of Medicine at Mount Sinai
David Muren Hwang, MD, PhD	Sunnybrook Health Sciences Centre
Gregory Kalemkerian, MD	University of Michigan
Mari Mino-Kenudson, MD	Massachusetts General Hospital
Ajit Paintal, MD	Northshore University
Lauren Ritterhouse, MD, PhD	Massachusetts General Hospital
Jennifer Sauter, MD	Memorial Sloan Kettering Cancer Center
Paul E Swanson, MD	University of Washington
Christina Ventura, MPH, MLS(ASCP)	College of American Pathologists
Ignacio I. Wistuba, MD	The University of Texas MD Anderson Cancer Center
Carol Colasacco, MLIS, CT(ASCP)	College of American Pathologists
Kearin Reid, MLS(ASCP)	College of American Pathologists
Lesley Souter, PhD	Nomadic EBM
Richard Walter Cartun, MS, PhD	Hartford Hospital - Pathology

No COIs to Report

Carol Colasacco, MLIS, CT(ASCP)	Christina Ventura, MPH, MLS(ASCP)
Lesley Souter, PhD	Kearin Reid, MLS(ASCP)
Richard Walter Cartun, MS, PhD	Ajit Paintal, MD
Mary Beth Beasley, MD	

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on May 10, 2021. The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.